GENE ONLINE|News &
Opinion
Blog

2018-05-15|

May 14, 2005: Piggybac as a Genetic Manipulation Tool for Analyzing Vertebrates, Patent Application Submitted to WIPO

by GeneOnline
Share To

The PiggyBac (PB) transposon is a mobile genetic element that can transpose between vectors and chromosomes via a “cut and paste” mechanism, and thus PiggyBac is an important tool related to transgenic technique. One specific technique using Piggybac as a tool for genetic manipulation and analysis in vertebrates was previously granted by the patent offices in the US, Europe, Canada, Japan, and China. On May 14, 2005, the inventors submitted a patent application to the World Intellectual Property Organization (WIPO) for this technique. Using PB transposon to transfer targeted gene fragment from vector into chromosome can effectively transplant targeted gene into the gene of certain organisms. In addition, PiggyBac technology is also equipped with a unique reversible characteristic.

Reference
http://europepmc.org/patents/PAT/CA2608481
https://en.wikipedia.org/wiki/PiggyBac_Transposon_System

Image Source
https://www.systembio.com/products/gene-expression-systems/piggybac-transposon/

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
US Court Rules Novartis Blockbuster Multiple Sclerosis Drug’s Patent Invalid
2022-06-22
Bristol Myers Squibb Requests $1.2 Billion Patent Revival From Supreme Court
2022-06-17
Illumina to Pay BGI $333M Following Infringement Case
2022-05-09
LATEST
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
EVENT
Scroll to Top